These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 19381523)

  • 1. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
    Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
    Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kill rates of preserved and preservative-free topical 8-methoxy fluoroquinolones against various strains of Staphylococcus.
    Hyon JY; Eser I; O'Brien TP
    J Cataract Refract Surg; 2009 Sep; 35(9):1609-13. PubMed ID: 19683161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoroquinolone therapy in a rabbit model of post-LASIK methicillin-resistant Staphylococcus aureus keratitis.
    Balzli CL; McCormick CC; Caballero AR; Huang B; Wigington L; Smith E; Tang A; O'Callaghan RJ
    J Cataract Refract Surg; 2008 Feb; 34(2):295-301. PubMed ID: 18242457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
    Hesje CK; Borsos SD; Blondeau JM
    J Ocul Pharmacol Ther; 2009 Aug; 25(4):329-34. PubMed ID: 19650708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin.
    Deramo VA; Lai JC; Fastenberg DM; Udell IJ
    Am J Ophthalmol; 2006 Nov; 142(5):721-5. PubMed ID: 16989762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).
    Schlech BA; Alfonso E
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S7-15. PubMed ID: 16257313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endophthalmitis after uncomplicated cataract surgery with the use of fourth-generation fluoroquinolones: a retrospective observational case series.
    Moshirfar M; Feiz V; Vitale AT; Wegelin JA; Basavanthappa S; Wolsey DH
    Ophthalmology; 2007 Apr; 114(4):686-91. PubMed ID: 17184840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus.
    Blondeau JM; Borsos S; Hesje CK
    J Chemother; 2007 Apr; 19(2):146-51. PubMed ID: 17434822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates.
    Asbell PA; Colby KA; Deng S; McDonnell P; Meisler DM; Raizman MB; Sheppard JD; Sahm DF
    Am J Ophthalmol; 2008 Jun; 145(6):951-958. PubMed ID: 18374299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the fourth-generation fluoroquinolones gatifloxacin 0.3% and moxifloxacin 0.5% in terms of ocular tolerability.
    Donnenfeld E; Perry HD; Chruscicki DA; Bitterman A; Cohn S; Solomon R
    Curr Med Res Opin; 2004 Nov; 20(11):1753-8. PubMed ID: 15537475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical ophthalmic moxifloxacin elicits minimal or no selection of fluoroquinolone resistance among bacteria isolated from the skin, nose, and throat.
    Lichtenstein SJ; De Leon L; Heller W; Marshall B; Cupp G; Foster K; McLean C; Levy S; Stroman DW
    J Pediatr Ophthalmol Strabismus; 2012; 49(2):88-97. PubMed ID: 22074357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
    Oliveira AD; D'Azevedo PA; Francisco W
    Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients.
    Kim DH; Stark WJ; O'Brien TP; Dick JD
    Ophthalmology; 2005 Nov; 112(11):1992-6. PubMed ID: 16183125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photorefractive keratectomy.
    Burka JM; Bower KS; Vanroekel RC; Stutzman RD; Kuzmowych CP; Howard RS
    Am J Ophthalmol; 2005 Jul; 140(1):83-7. PubMed ID: 15953577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of endophthalmitis by collagen shields presoaked in fourth-generation fluoroquinolones versus by topical prophylaxis.
    Haugen B; Werner L; Romaniv N; Haymore J; Kleinmann G; Mamalis N; Olson RJ
    J Cataract Refract Surg; 2008 May; 34(5):853-8. PubMed ID: 18471646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ophthalmic infections and their anti-infective challenges.
    Alfonso E; Crider J
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S1-6. PubMed ID: 16257307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens.
    Callegan MC; Ramirez R; Kane ST; Cochran DC; Jensen H
    Adv Ther; 2003; 20(5):246-52. PubMed ID: 14964344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model.
    Kowalski RP; Romanowski EG; Mah FS; Yates KA; Gordon YJ
    Am J Ophthalmol; 2005 Sep; 140(3):497-504. PubMed ID: 16083841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of fluoroquinolone kinetics of kill in susceptible and resistant gram-positive conjunctival pathogens.
    D'Arienzo PA; Wagner RS; Jamison T; Bell B; Dajcs JJ; Stroman DW
    Adv Ther; 2010 Jan; 27(1):39-47. PubMed ID: 20174904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis.
    Sanders ME; Norcross EW; Moore QC; Shafiee A; Marquart ME
    Cornea; 2009 Oct; 28(9):1055-60. PubMed ID: 19724203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.